Press Release: Entheon Biomedical Announces EEG Patent Application & Provides Research Update


December 17, 2021· Vancouver, British Columbia–(Newsfile Corp. – December 16, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its patent portfolio as well as nonclinical and clinical programs. US Provisional Patent Filed In furtherance of its program, the Company filed US Provisional Patent Application No. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. “Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. “With the filing of our provisional patent application, Entheon is building an IP foundation to better facilitate safe and precise use of psychedelics to deliver improved patient outcomes.” In Vivo Toxicity Assays Completed Further to the Corporate Update provided on November 24, 2021, the Company is pleased to announce further progress on its nonclinical program. In vivo toxicity assays have been completed with our CRO partner, with a final report expected in the coming weeks. Along with the previously completed in vitro assays, these studies serve as the benchmark for further preclinical work in 2022 and will contribute to regulatory submissions as the company advances its DMT program. EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial The Company is pleased to confirm that it is on track to submit its regulatory package to the Dutch ethics committee in early 2022 for its upcoming human trial. EBRX-101, a study that…

Excerpt only …
Source : Press Release: Entheon Biomedical Announces EEG Patent Application & Provides Research Update

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.